Evidence map›Paper›PMID 41639223›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Value of [

Jingjie Qin, Chengqiang Li, Yong Huang, Yuqin Jin, Xiaoshan Liu, Xudong Hu, Jian Zhu, Junya San, Hongbo Wu, Xue Meng and 2 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Radiation oncology at a new frontier: Hotspots, challenges, and emerging advances.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jingjie Qin *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Chengqiang Li *Department of Radiation Oncology Physics & Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yong HuangDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yuqin JinDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xiaoshan LiuDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xudong HuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jian ZhuDepartment of Radiation Oncology Physics & Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Junya SanDepartment of Radiology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Hongbo WuDepartment of Nuclear Medicine PET Center, Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xue MengDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jinming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yuchun WeiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. yuchunwei0000@foxmail.com.ORCID 0000-0002-7198-9915

Funding

China Postdoctoral Science Foundation 2023M731484Collaborative Academic Innovation Project of Shandong Cancer Hospital TS009National Natural Science Foundation of China 82203218Natural Science Foundation of Shandong Province ZR2021QH008Natural Science Foundation of Shandong Province ZR2022QH188Natural Science Foundation of Shandong Province ZR2024YQ073the Major National Science and Technology Project 2024ZD0519901
6 · The paper itself

Abstract

purposeTo evaluate the usefulness of [ MATERIALS AND

methodsIn this secondary analysis of a prospective trial, patients with stage I-III lung cancer who underwent [

resultsFifty-one patients (median age, 64 years; 38 males [74.5%]) were evaluated. Statistically significant differences in GTVs based on CE-CT, [

conclusion[

trial registrationThis study was approved by the Clinical Research Ethics Committee of our institution.

Indexed as

Fluorodeoxyglucose F18Heterocyclic CompoundsLung NeoplasmsPositron Emission Tomography Computed TomographyRadiotherapy, Image-GuidedRadiotherapy Planning, Computer-AssistedAgedAged, 80 and overContrast MediaFemaleFibroblast Activation Protein AlphaHeterocyclic Compounds, 1-RingHumansMaleMiddle AgedNeoplasm Staging1,4,7-triazacyclononane-N,N',N''-triacetic acidContrast MediaFibroblast Activation Protein AlphaFluorodeoxyglucose F18Heterocyclic CompoundsHeterocyclic Compounds, 1-RingFAPI PET/CTGross tumor volumeIMRT/IMPTLung cancerRadiotherapy

Identifiers

PMID41639223
PMCPMC13121188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.